Prediction: The Trump Bull Market Will Soon End -- But These 2 Stocks Will Keep Winning Anyway

The article argues that the U.S. stock market’s post-inauguration rally may be nearing exhaustion, citing the S&P 500’s stretched valuation and persistent inflationary pressure from energy prices and CPI. Despite this cautious macro view, the piece highlights two stocks that could continue outperforming even if the broader bull market cools: Eli Lilly and Johnson & Johnson. Lilly is framed as a durable growth story due to its obesity-drug leadership, double- and triple-digit revenue growth in key products, and pipeline catalysts including positive phase 3 data for retatrutide and the launch of oral weight-loss drug Foundayo. Johnson & Johnson is presented as a steadier defensive winner, with strong recent sales growth in both innovative medicine and medtech, plus management goals for $100 billion in annual revenue and double-digit growth by decade-end. Overall, the market tone is cautious on the index but constructive on healthcare stocks.